Stocks
Pharvaris N.V.PHVS
NASDAQHealthcareBiotechnology$31.41
Price as of · delayed, not real-time
A clinical-stage biopharmaceutical company developing oral therapies for rare genetic angioedema disorders, with a lead candidate targeting hereditary angioedema. Its pipeline focuses on small-molecule plasma kallikrein inhibitors, a mechanism with potential to offer convenient prophylaxis and on-demand treatment. Investors track the company for its late-stage data readouts and the commercial opportunity in a niche but growing market.
52W Range: $21.02-$43.25
Congressional Interest in Pharvaris N.V. (PHVS)
No congressional trades have been disclosed for Pharvaris N.V. (PHVS) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading PHVS?
No congressional trades found for this stock.